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aripiprazole (RR:1.29, 95%CI:1.05–1.58), haloperidol (RR:1.29, 95%CI:1.03–1.62). 
Lithium followed by divalproex ER were the most effective mood stabilisers: lithium 
(RR:1.73, 95%CI:1.08–2.79), divalproex ER (RR:1.40, 95%CI:1.09–1.80), dival-
proex (1.12, 95%CI:0.81–1.55), carbamazepine ER (not available). The results 
for response reported that risperidone and quetiapine XR were the most effective 
antipsychotics: risperidone (RR:1.77, 95%CI:1.50–2.09), quetiapine XR (RR:1.61, 
95%CI:1.23–2.10), olanzapine (RR:1.54, 95%CI:1.23–1.92), aripiprazole (RR:1.46, 
95%CI:1.26–1.70), haloperidol (RR:1.41, 95%CI:1.19–1.66). Carbamazepine ER 
followed by lithium were the most effective mood stabilisers: carbamazepine ER 
(RR:2.01, 95%CI:1.55–2.61), lithium (RR:1.57, 95%CI:1.28–1.92), divalproex 
(RR:1.46, 95%CI:1.10–1.93), divalproex ER (RR:1.45, 95%CI:1.12–1.87). Due 
to incomplete reporting, the pooled mean difference in YMRS was considered 
unreliable. CONCLUSIONS: Selecting the right pharmacological treatment strategy 
which optimises remission is key to maximising patient outcomes and efﬁcient use of 
health care resources. This analysis suggests that risperidone, quetiapine XR and 
lithium are promising treatment options for bipolar I mania. 1. Smith, Bipolar Disord. 
2007;9:551–560.
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EFFECTIVENESS AND COST-EFFECTIVENESS OF LIFESTYLE 
INTERVENTIONS IN PERSONS WITH SEVERE MENTAL DISORDERS.  
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OBJECTIVES: When compared to the general population, people with severe         
mental disorder (SMD) more commonly show obesity, sedentary lifestyles and 
poor dietary choices. This review examines the effectiveness and cost-effectiveness of 
lifestyle interventions on physical activity and dietary choices in people with 
SMD. Included health outcomes were changes in weight, body mass index (BMI) 
and quality of life. METHODS: A systematic E-search strategy was conducted      
using Medline, Web of Science and CINAHL to select articles of lifestyle interventions 
targeting exercise and dietary choices in people with SMD. In addition, the reference 
lists of retrieved articles from the E-databases were hand-searched. RESULTS: 
The search strategy produced 14 randomized and non-randomized comparative trials 
that met the inclusion criteria. Mean duration of the interventions was 20.0 o 10.84 
weeks. Weight loss was reported in 11 studies, with a mean weight change of 1.96 
o 1.84 kg in the intervention groups versus 1.77 o 2.12 kg in the control groups.      
Changes in BMI were 0.87 o 0.69 kg/m² and   0.64 o 0.96 kg/m² respectively in    
intervention and control groups. Differences in changes in weight and BMI between 
intervention and control groups were statistically signiﬁcant in nine studies. The results 
also suggest that quality of life and general health could beneﬁt from these kinds of 
interventions. For example, subjective improvements in quality of life (p  0.047) and 
in overall health (p  0.023) were found in the study of Evans et al. (2005). In 
none of the studies, however, cost-effectiveness was examined. CONCLUSIONS: 
Small weight loss through lifestyle interventions targeting physical activity and 
dietary choices is possible in people with SMD. This is promising given the high 
prevalence of sedentary lifestyles and poor dietary choices and the effects of some 
atypical antipsychotics on weight gain. Further study of both effectiveness and cost-
effectiveness (including the most cost-effective ‘dose’) of lifestyle interventions in 
people with SMD is required.
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DIFFERENCES BETWEEN CHILDREN AND ADOLESCENTS IN 
TREATMENT RESPONSE TO ATOMOXETINE AND THE CORRELATION 
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OBJECTIVES: To explore differences between age subgroups in QOL in atomoxetine 
treated patients and evaluate correlations between ADHD core symptoms and QOL. 
METHODS: Pooled data of 5 similar clinical atomoxetine trials (8–12 weeks follow-
up, 3 placebo-controlled, 2 open-label) were included in the analysis. All studies used 
the ADHD-RS and the CHIP-CE instruments. Treatment group differences (effect size 
vs. placebo) in CHIP-CE score changes were compared between different age groups 
( /&GE;12YRS);  RESULTS: A total of 611 children (12 yrs) and 183 adolescents 
(q12 yrs) were included. Baseline CHIP-CE total t-scores (mean o SD; norm: 50 o 10) 
were similar in children (29.3 o 11.58) and adolescents (27.5 o 12.29) (p  0.296). 
Greater impairments in the CHIP-CE ‘achievement’ domain were seen in adolescents 
than children (t-scores 31.0 o 10.26 and 28.9 o 10.71, respectively; p  0.05); there 
were no clinically relevant differences in other domains. For the CHIP-CE ‘risk avoid-
ance’ domain, the effect size of atomoxetine was higher in adolescents than in children 
(0.83, p  0.001 and 0.37, p  0.005; age*treatment interaction p  0.059); age group 
differences for other domains and CHIP-CE total scores were not clinically relevant. 
ADHD-RS/CHIP-CE correlations were low at baseline but moderate for change 
from baseline being similar in age groups. Only the ‘risk avoidance’ domain showed 
a trend towards lower correlation of change in adolescents (r  0.384 and r  0.545). 
CONCLUSIONS: Both age groups showed a clinically relevant impairment of QoL 
at baseline which was similar for adolescents and children in four out of ﬁve CHIP-CE 
domains. In both groups, atomoxetine was effective in improving QoL. For the ‘risk 
avoidance’ domain, the effect size of atomoxetine was larger in adolescents than in 
children, while the ADHD-RS/CHIP-CE correlation was lower in adolescents, indicat-
ing a lower association with core symptoms.
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OBJECTIVES: The objective was to compare occurrence of relapse according to 
antipsychotic treatment (monotherapy vs polypharmacy), in a 2 year observational 
cohort of 288 French schizophrenic patients, using different methods of adjustment. 
METHODS: Relapse was deﬁned by a usual, clinically well reproducible and validated 
deﬁnition. The occurrence of relapse between patients receiving one antipsychotic to 
patients receiving more than one antipsychotic was compared according to a Cox 
model including or not the propensity score (PS). The propensity score was calculated 
on socio-economic and demographic information, clinical variables, quality of life, 
medication information and attitude toward treatment. Cox models were built accord-
ing to four usual methods to calculate the propensity score: 1—stepwise PS, continu-
ous, 2—non stepwise PS, continuous, 3—non stepwise PS, quintiles 4—non stepwise 
PS quintiles used to stratify the sample. We also used standard adjustment using all 
variables included in the model estimating the PS. Likelihood, Akaike’s information 
criterion (AIC) criterion and Schwatz’s Bayesian Criterion (SBC) criterion were used 
to compare the models. RESULTS: The standard cox model reports signiﬁcant 
decrease of relapse in patient receiving polytherapy. Consistently the four models 
based on propensity scoring methods did not ﬁnd any difference between the two 
populations. The model that optimizes all criteria (2logL, AIC and SBC) is the model 
using the stratiﬁcation on the propensity score. CONCLUSIONS: Polytherapy is not 
associated to a reduction of relapse while consistently literature reports major risk 
associated to polypharmacy including increased mortality. The use of propensity 
scoring is well established for observational data and this study illustrate that standard 
regression could be misleading.
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TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER (ADHD): DATA FROM THE 
NETHERLANDS
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OBJECTIVES: To evaluate time to optimization of dose in children with ADHD in 
The Netherlands. METHODS: Claims data from the PHARMO medical record 
linkage system database from 48 geo-demographic areas in The Netherlands (2003–
2006) were analyzed from newly treated ADHD patients aged 6–17 years. Patients 
were followed for at least 12 months after treatment initiation with methylphenidate 
or atomoxetine. Demographic and medication characteristics at treatment initiation, 
and concurrent psychotropic treatments in the year before ADHD treatment initiation 
were recorded. For this analysis, only patients with ³5 dispensings for any ADHD drug 
during follow-up and no missing information on type of drug, strength, and number 
of pills per day were included. Optimized dosing regimen was deﬁned as no change 
in type of drug, strength, and number of pills per day for 5 consecutive dispensings 
(no time restriction between dispensings). Time to optimized dosing regimen was 
deﬁned as the number of days between the ﬁrst dispensing for an ADHD drug (cohort 
entry date) and the ﬁrst of ﬁve unchanged dispensings. RESULTS: Of 4909 children 
initiating treatment from 2003–2006, 3159 met selection criteria. The proportion of 
patients reaching dosing optimization with initial treatment was 69.8% for atomox-
etine (ATX; n  37), 74.8% for short-acting methylphenidate (SA; n  2017), and 
82.4% for long-acting methylphenidate (LA; n  262; P  0.05 for both ATX and SA 
vs LA). The median number of days required to reach optimal dosing regimen was 
49 across the total sample. Among patients achieving dose optimization, those initiat-
ing treatment with LA had a signiﬁcantly shorter time to dose optimization (14 days) 
than patients initially treated with SA (56 days; P  0.001) or ATX (31 days; 
P  0.05). CONCLUSIONS: Time to optimization of dosing regimen in children 
with ADHD in The Netherlands varied according to treatment chosen at initiation 
and was shortest for long-acting methylphenidate. Supported by funding from Shire 
Development Inc.
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OBJECTIVES: Alzheimer’s disease is an irreversible progressive disease that affects 
cognitive, behavioural and functional abilities. The prevalence of Alzheimer’s disease 
is increasing as the world’s population is aging. The primary aim of the study was to 
determine the prescribing patterns and cost of drugs for Alzheimer’s disease in a 
private health care sector patient population. METHODS: A retrospective, exposure-
cohort pharmacoepidemiological study was conducted. Data were obtained from a 
South African private pharmacy group for 2008. The database consisted of 1,578,346 
medicine records. RESULTS: A total of 588 patients (326 females and 262 males) 
received 2623 medicine items for Alzheimer’s disease at a cost of R1,563,701.18 
(average cost per item R596.15). The average age of patients was 75.54 (SD  10.48) 
years, with 78.40% of patients between 70 and 89 years of age. Donepezil was the 
most frequently prescribed active ingredient (37.09%), followed by galantamine 
(36.94%). Donepezil accounted for 39.50% of the cost of Alzheimer medication. No 
notable differences in prescribing patterns were observed over the 12-month period. 
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The average cost per prescription was R634.76 for donepezil, and R551.35 for 
memantine. Only 5.27% of patients were prescribed more than one active ingredient 
for Alzheimer’s disease during the year (mostly donepezil or galantamine, together 
with memantine). Average Prescribed Daily Doses (PDDs) of all active ingredients 
were generally lower than their respective Deﬁned Daily Doses (DDDs). The average 
PDD for donepezil was 7.45 mg (DDD  7.5 mg), galantamine 13.56 mg (DDD  
16 mg), for memantine was 17.46 mg (DDD  20 mg) and for rivastigmine was 
6.89 mg (DDD  9 mg). CONCLUSIONS: The results were similar to those of previ-
ous South African studies. Treatment outcomes could not be measured and it is recom-
mended that qualitative studies be undertaken to determine the cost-effectiveness of 
the different treatment options according to family members and caretakers.
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OBJECTIVES: Prescribing an initial optimum therapeutic dose while avoiding dose-
related side effects is important in the treatment of major depressive disorder (MDD). 
Many factors may inﬂuence a physician’s decision on an antidepressant choice and 
starting dose. The purpose of the present study was to identify the pretreatment predic-
tors of initial high-dose prescription of duloxetine in patients with MDD in real world 
clinical settings. METHODS: A total of 10,128 patients with MDD who were selected 
from a large commercially administrative claims database and were initiated on 
duloxetine between July 1, 2005 and June 30, 2006 were included in the analysis. 
Patients had no prescriptions of duloxetine in the 6 months prior to duloxetine treat-
ment. For patients who had continuous enrollment for 12 months prior to duloxetine 
treatment, the associations between demographic characteristics and pre-initiation 
clinical variables in the prior 1 year and initial high-dose (60 mg/day) prescription 
compared with average dosage (60 mg/day) prescription were examined by logistic 
regression. RESULTS: Of the sample, 31.2% were initially prescribed duloxetine less 
than 60 mg/day; 62.1%, 60 mg/day; and 6.8%, 60 mg/day. Compared with average-
dose patients, high-dose patients had more comorbidities; used more benzodiazepine, 
anxiolytics, atypical antipsychotics, lithium, psychostimulants, and anticonvulsants; 
and used more medical care services with higher pharmacy and medical costs in the 
prior 1 year. After adjustment for health plan type and geographic region of residence, 
the following factors were independently associated with initial high-dose prescription: 
prior use of psychostimulants (OR  1.45), no prior use of selective serotonin reuptake 
inhibitors (OR  1.28), physician specialty (psychiatrist vs. non-psychiatrist, OR  
1.43), and high medical cost in the prior 1 year (OR  2.12). CONCLUSIONS: 
 Multiple demographic and clinical characteristics and prior health care service utiliza-
tion are associated with initial high-dose duloxetine prescription. High-dose patients 
may represent a group of complex patients with high medical cost who need intensive 
medical intervention.
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OBJECTIVES: The appropriate and optimal health care resources of schizophrenic 
patients could beneﬁt from identifying predictive factors for hospitalization. The 
purpose of this study was to identify those factors of hospitalization for French 
schizophrenic patients out of a 2 years prospective cohort of 288 patients. METHODS: 
This study collected clinical, patient reported outcomes, patient management, care 
giver involvement and resource utilizations data every six months. The patients who 
were at least once hospitalized during the study were compared to the patients who 
were not hospitalized during the study. Predictive factors of hospitalization were 
identiﬁed by using a Cox model with all appropriate variables. RESULTS: To be under 
antidepressant/depressed, to have negative attitude toward medicine and former hos-     
pitalizations appear to be good predictors of hospitalisation in French schizophrenic 
patients. While living alone and subjective side effect were associated to reduce the 
risk of hospitalisation. Depression is known to be associated to poor outcome however 
few comprehensive studies include depression as a confounding factor. Negative atti-
tude toward medicine as well as former hospitalisation are likely to be associated to 
increase the risk of hospitalisation. Unexpectedly perceived side effects and living alone        
were associated to reduce hospitalisation. The authors do not have clear explanation 
but hypothesis that would require to be tested in further studies. CONCLUSIONS: 
Unless appropriate confounding variables are included in resource utilization studies, 
results should considered with great caution.
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DRUG PRESCRIBING IN THE ITALIAN GENERAL POPULATION: 
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OBJECTIVES: to assess the prevalence, incidence and persistence of AntiDepressant         
(AD) drug therapy in an area of Campania, a region in the South of Italy, during the 
years 2005–2007. METHODS: we collected, from an administrative prescription      
database covering a population of 441,317 individuals, all prescriptions for ADs 
reimbursed in the years 2005–2007. We calculated the number of subjects receiving 
at least one ADs prescription, to estimate the annual prevalence and incidence of AD 
users. Among incidence users we evaluated the percentage of individuals remaining 
on therapy at 12 months following the ﬁrst observed AD prescription. The cumulative 
persistence of each medication was estimated using the Kaplan-Meier method. We      
identiﬁed users of different ADs types: tricyclic antidepressants (TCAs), selective 
serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibi-    
tors (SNRIs) and other antidepressants.   RESULTS: A progressive rise in prevalence     
rates was observed during the 3-years period. 1-year prevalence of AD use was 5.08 
per 100,000 inhabitants in the year 2007. Prevalence was higher for females (2005: 
5.67; 2006: 6.15; 2007: 6.61) and increased during three years period with increasing 
age. Prevalence of SSRI usage markedly increased from 3.45 in 2005 to 4.04 in 2007. 
A 1-year incidence of AD treatment was 2.79 per 100,000 person-year in 2006. SSRIs 
accounted for almost two-thirds of total new treatments with ADs. The analysis of 
therapy persistence revealed that the 80% of AD users discontinued medication within 
60 days; there are no difference among different drug classes. CONCLUSIONS: The 
results of the study indicated an increasing prevalence of AD medication usage during 
the 2005–2007 years. This increase appears to be mostly related to SSRI, in particular 
those recently marketed. The non-persistence is very frequent in AD users, only rarely 
the duration of treatment was consistent with recommendations for depression 
therapy.
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SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK 
OF BEING IN A SPECIFIC DISEASE STATE
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As a ﬁrst step to model schizophrenia, we are proposing a research project aimed at 
better understanding the factors associated with speciﬁc disease states associated 
with schizophrenia. OBJECTIVES: To evaluate the factors associated with the risk of 
being in a speciﬁc disease state of schizophrenia. METHODS: The model was based 
on data from RAMQ and Med-Echo databases. A total of 12,754 newly diagnosed 
patients with schizophrenia patients were identiﬁed. Six discrete disease states were 
deﬁned within the model (ﬁrst episode—FE, low dependency state—LDS, high depen-
dency state—HDS, Stable, Well and Death) and patients’ movements between these 
disease states enabled 17 risks to be identiﬁed. To evaluate factors associated to the 
risk of being in each disease state, we constructed ﬁve risk functions based on Cox 
proportional hazard analysis for competing risks. The risk factors included in the 
models were age, gender, social assistance status, severity of schizophrenia, depression, 
anxiolytic drugs use and other mental disorders. RESULTS: After the FE of schizo-
phrenia, 69.8% of patients transitioned to LDS, 11.2% to HDS, 1% to the death 
state and 18% into the Well state. Being male (HR: 0.93, 95% CI: 0.89–0.97) or 
older (HR: 0.94, 95% CI: 0.91–0.96) was associated with a decreasing risk of moving 
to LDS after being FE. In contrast, being on social assistance, depressed, using anxio-
lytic drugs or being diagnosed with other mental disorders were associated with 
an increased risk of being in a LDS after a FE, ranging from 1.11 to 1.55 folds. 
CONCLUSIONS: Some of our results are consistent with those obtained from the 
published literature. Based on these risk functions we estimate individual transition 
probabilities that will be used in the ﬁrst Canadian model of schizophrenia incorporat-
ing transition probabilities adjusted for individual risk factors proﬁles using Canadian 
data.
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1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary
OBJECTIVES: In Western Hungary the number of women with hypertension increased 
with 21%, the number of patients with ischemic heart problems increased with 46% 
between 2005 and 2007. The most probable reason of this sudden increase among 
the life quality factors is the increasing of chronic stress. The rate of chronic stress 
and the effectiveness of coping were measured between workers from a regional mul-
tinational ﬁrm with a cross sectional examination in 2008. METHODS: Sampling is 
representative regarding to the Western Hungarian population, 900 workers were 
examined with unknown presumption. Data collection was made with Richard Rahe 
Short Questionnaire about Stress and Coping standard measurement device. The 
analysis of the data was done with SPSS 17.0 and Epi Info 3.5.1 programs, two sample 
t-test and logistic regression calculation was made. RESULTS: From the ﬁve scales 
measuring stress women showed alarming signs on three scales (sanitary problems, 
psychological symptoms and the A- and C-type personal characteristic scales), and 
men on one scale (the A- and C-type personal characteristic). The difference is signiﬁ-
cant (p  0.000). From the ﬁve scales measuring coping men and women equally 
showed alarming signs on the social support scale as a deﬁcit. Women ﬁght against 
stress with less efﬁciency on the scale of habits related to health (p  0.001). The most 
deﬁning stress indicating factor in case of man is sanitary problems (OR  2.27, p  
0.02), and personal characteristics in case of woman (OR  3.34, p  0.002). The 
most important inﬂuencing factor in case of coping is the sense of coherence (at women 
OR  7.9, p  0.000, at men OR  4.5, p  0.000). CONCLUSIONS: This survey 
shows that chronic stress is complex, but it can be examined individually and in teams 
with proper methods. This topic is current in relation to national health: chronic 
